At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 109 enrolled
Drug / intervention
NC318drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
In Brief
A Phase 2 clinical trial evaluating NC318 for Advanced or Metastatic Solid Tumors and 8 related conditions. Completed, enrolled 109 participants across 6 sites.
Detailed Summary
This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Melanoma, CRC, Urothelial Carcinoma, Cholangiocarcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartOct 2018
Primary CompletionApr 2023
TodayJul 2026
First PostedSep 11, 2018
Enrollment StartOct 1, 2018
Primary CompletionApr 11, 2023
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 7.8 years ago
Interventions
NC318drug
NC318 is an experimental antibody drug that may make the immune response more active against cancer.